Copied to clipboard!

Biomarker analysis and treatment dynamics following preoperative ipilimumab plus nivolumab in locally advanced urothelial cancer from the phase 1B NABUCCO study

In the current analysis of the full NABUCCO trial population (cohorts 1 and 2), we aimed to explore both potential biomarkers for response to combination ICB, as well as treatment dynamics to gain a better understanding of the effects of ICB on the urothelial cancer tumor microenvironment (TME).

Type: RNASeq
Archiver: European Genome-phenome Archive (EGA)

2 Datasets 1 Publication

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD50000002556	RNAseq of baseline tumor tissue obtained during TUR to identify biomarkers for ICB response in MIBC. Constitutes the entire NABUCCO phase 1B clinical trial cohort. The NABUCCO 1 trial contains 18 single-end RNA sequenced samples and 6 paired end RNA sequenced samples. The NABUCCO 2 trial contains 25 paired end RNA sequenced samples. The file type for all of the samples is FASTQ. For single end RNA sequencing, Illumina HiSeq 2500 was used as the sequencing platform. For paired end RNA sequencing, the Illumina NovaSeq 6000 was used as the sequencing platform.	Illumina HiSeq 2500 Illumina NovaSeq 6000	50
EGAD50000002557	ScRNAseq of CD3 T-cells isolated from post-treatment bladder tissue from 2 samples from the NABUCCO 1 trial. Paired-end RNAsequencing was used on the Illumina NovaSeq 6000 sequencing platform.	Illumina NovaSeq 6000	2

Publications	Citations
Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study. Stockem CF, Gil-Jimenez A, Ali H, van Dorp J, van Dijk N, van Montfoort ML, Alkemade M, Broeks A, Seignette IM, Hooijberg E, Brugman W, Voogd R, van Rhijn BWG, Mertens LS, de Feijter JM, Mehra N, van der Heijden AG, Meijer RP, Suelmann BBM, Scheper W, Wessels LFA, Vis DJ, van der Heijden MS. Clin Cancer Res 31: 2025 3897-3906	0

Publications

Citations

Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study.
Stockem CF, Gil-Jimenez A, Ali H, van Dorp J, van Dijk N, van Montfoort ML, Alkemade M, Broeks A, Seignette IM, Hooijberg E, Brugman W, Voogd R, van Rhijn BWG, Mertens LS, de Feijter JM, Mehra N, van der Heijden AG, Meijer RP, Suelmann BBM, Scheper W, Wessels LFA, Vis DJ, van der Heijden MS. Clin Cancer Res 31: 2025 3897-3906